BIBLIOGRAFÍA

1. Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med 1999; 341(19): 1447-57.

2. Kim-Mitsuyama S. Perspective of calcium antagonist. Clin Calcium 2005; 15(1): 81-6.

3. Mojarrad JS, Miri R, Knaus EE. Design and synthesis of methyl 2-methyl-7,7-dihalo-5-phenyl-2-azabicyclo[4.1.0]hept-3-ene-4-carboxylates with calcium channel antagonist activity. Bioorg Med Chem 2004; 12(12): 3215-20.

4. Koldas L, Ayan F, Ikitimur B. Short-term effects of rilmenidine on left ventricular hypertrophy and systolic and diastolic function in patients with essential hypertension: comparison with an angiotensin converting enzyme inhibitor and a calcium antagonist. Jpn Heart J 2003; 44(5): 693-704 [Resumen].

5. Shan R, Velazquez C, Knaus EE. Syntheses, calcium channel agonist-antagonist modulation activities, and nitric oxide release studies of nitrooxyalkyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2,1,3-benzoxadiazol-4-yl)pyridine-5-carboxylate racemates, enantiomers, and diastereomers. J Med Chem 2004; 47(1): 254-61.

6. Newton CRH, Delgado JH, Gómez HF. Calcium and beta receptor antagonist overdose: A review and update of pharmacological principles and management. Semin Respir Crit Care Med 2002; 23(1): 19-25.

7. Mills TA, Kawji MM, Cataldo VD, Pappas ND, O'Meallie LP, Breaux DM, et al. Profound sinus bradycardia due to diltiazem, verapamil, and/or beta-adrenergic blocking drugs. J La State Med Soc 2004; 156(6): 327-31.

8. Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004; 65(6): 1991-2002.

9. Boizant LM, Casas S, Gross MC, Martínez Y. Papel de los bloqueadores de los canales de calcio en la prevención de eventos cardiovasculares. MEDISAN 2000; 4(4): 42-8.

10. Keck M, Sauerbrey-Wullkopf N, Regourd E, Clemens A. Safety and antihypertensive efficacy of the dihydropyridine calcium antagonist Amlodipine besylate – results from an observational study in 9,672 patients. MMW Fortschr Med 2004; 146: 115-21.

11. Niwa T, Shiraga T, Hashimoto T, Kagayama A. Effect of nilvadipine, a dihydropyridine calcium antagonist, on cytochrome P450 activities in human hepatic microsomes. Biol Pharm Bull 2004; 27(3): 415-7.

12. Ma B, Prueksaritanont T, Lin JH. Drug Interactions with Calcium Channel Blockers: Possible Involvement of Metabolite-Intermediate Complexation with CYP3A. Drug Metab Dispos 2000; 28(2): 125-30.

13. Hattori T, Hirai K, Wang P, Fujimura S. Proliferation of cultured human gingival fibroblasts caused by isradipine, a dihydropyridine-derivative calcium antagonist. Eur J Med Res 2004; 9(6): 313-5.

14. Hansson L. Morbidity and mortality with dihydropyridines. Blood Press Suppl 1998; 1: 30-32.

15. Kato T, Amano A, Kamisaki Y, Morisaki I. Enhancement of nifedipine-induced gingival overgrowth by concomitant ketoconazole in rats. Pharmacology 2005; 74(1): 45-50.

16. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. Lancet 1990; 335(8698): 1109-13.

17. Moser M, Cheitlin MD, Gifford R. Treatment of high blood pressure in the elderly. A position paper from the Society of Geriatric Cardiology. [Artículo en internet]. [Consultado 22/09/2005]. Disponible en: http://www.sgcard.org/pp treatment.html

18. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium channel blocker or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356(9227): 366-372.

19. Nifedipine oral. Medscape Drug Refernce. [Artículo en internet]. [Consultado 24/11/2005]. Disponible en: http://www.medscape.com/druginfo/dosage?cid=med&drugid=8681&drugname=Nifedipine+Oral&monotype=default

20. Calvo DM, Cires M, Cruz MA, Delgado I, Freijoso E, Pérez J, et al. Formulario nacional de medicamentos. Ciudad de La Habana: Editorial Ciencias Médicas, 2003; p. 293, 302, 325.

21. Galetin A, Clarke SE, Houston JB. Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos 2002; 30(12): 1512-22.

22. Klotz U. Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist. Arzneimittelforschung 2002; 52(3): 155-61 [Resumen].

23. Gupta MC, Garg SK, Das BP, Bhargava VK. Effect of nimodipine, a dihydropyridine calcium channel antagonist on the pharmacokinetics of carbamazepine in rhesus monkeys. Indian J Physiol Pharmacol 2003; 47(3): 347-51.

24. Galetin A, Ito K, Hallifax D, Houston JB. CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J Pharmacol Exp Ther 2005; 314(1): 180-90.

25. Chow FS, Jusko WJ. Immunosuppressive interactions among calcium channel antagonists and selected corticosteroids and macrolides using human whole blood lymphocytes. Drug Metab Pharmacokinet 2004; 19(6): 413-21.

26. Walsky RL, Gaman EA, Obach RS. Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 2005; 45(1): 68-78.

27. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290(21): 2805-16.

28. Fujino T, Sumitomo K, Hasebe N, Kikuchi K. Effects of calcium channel blockers in atherosclerosis and cardiovascular event and oxidative vascular damage. Clin Calcium 2004; 14(1): 119-27.

29. Bendersky M. Los antagonistas cálcicos y la prevención cardiovascular. Rev Fed Arg Cardiol 2005; 34: 55-60.

30. Amano T, Aihua Z, Matsubayashi H, Seki T, Serikawa T, Sasa M, et al. Antiepileptic effects of single and repeated oral administrations of S-312-d, a novel calcium channel antagonist, on tonic convulsions in spontaneously epileptic rats. J Pharmacol Sci 2004; 95(3): 355-62.

31. Borghi C, Prandin MG, Dormi A, Ambrosioni E; Study Group of the Regional Unit of the Italian Society of Hypertension. Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press Suppl 2003; 1: 14-21.

32. Taddei S, Virdis A, Ghiadoni L, Versari D, Salvetti G, Magagna A, et al. Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension. Hypertension 2003; 41(4): 950-5.